What's in Phil Mickelson's Portfolio? Clorox, Barclays and 3 More He Endorses

NEW YORK (TheStreet) -- Back in February 2011 billionaire investor Carl Icahn revealed in a public filing that he had taken a stake in Clorox (CLX), beginning a take-over bid for the company.

One of the world's most popular golfers, Phil Mickelson, added shares of Clorox to his portfolio around the same time. Insider trading? He denies it and is cooperating with the authorities.

But Clorox isn't Mickelson's only stock holding. His portfolio includes five companies for which he does endorsements.

I doubt the three-time Masters Champ (2004, 2006 & 2010), PGA Champion (2005) and the British Open winner (2013) will lose one dime of endorsement dollars. The $180 million golf champ getting ready for the U.S. Open Championship match on June 12 in Pinehurst, North Carolina.

Here are the components in the Phil Mickelson portfolio.

Clorox (CLX) ($88.59) set an all-time intraday high at $96.76 but I wonder whether or not Phil washed his hands of this company. The stock is just above its 200-day simple moving average at $88.10.

The weekly chart is negative given a close this week below its five-week modified moving average at $88.39 which indicates risk to its 200-week simple moving average at $75.32. Annual value levels are $84.10 and $74.09 with semiannual pivots at $86.84 and $88.73 and quarterly risky level at $95.67. This profile suggests that if Phil still owns the stock its time to sell.

Callaway Golf (ELY) ($7.89) is Phil's most important endorsement as he must use Callaway products. If Phil can keep the ball in the fairway with his Big Bertha driver he will win the U.S. Open on June 15. If he misses the fairway he's still the best on the PGA Tour with those short-wedge shots. His biggest issue that could prevent winning is missing short putts, which has been his Achilles Heel in many majors. Despite the cloud of his 2011 Clorox trade the odds of Mickelson win is 14 to 1.

The stock set a multiyear intraday high at $10.35 on April 1 and is now below its 200-day SMA at $8.25 with its 2014 intraday low set at $7.51 on May 20. The weekly chart is negative with its five-week MMA at $8.41 and its 200-week SMA at $6.87. An annual value level is $6.73 with a semiannual risky level at $8.45. Buy the clubs, not the stock.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Approves First 'Biosimilar' for Cancer Treatment

Amgen Builds on a Breakout

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback